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Abstract
On March 11th, 2020, COVID-19 was declared a worldwide pandemic. Publicly available testing has lagged, and tech entre-
preneurs have quickly volunteered to fill this gap. Over the last two decades, genetic testing ordered outside of a clinic and
without the involvement of a physician has been a way for the average individual to get genetic testing. In this commentary, we
discuss the lessons learned from this parallel case from genetics and suggest regulatory caution in establishing direct-to-consumer
COVID testing.
OnMarch 11th, 2020, theWorld Health Organization official-
ly declared the coronavirus disease “COVID-19” a worldwide
pandemic. At the time of writing, there are nearly 5,000,000
confirmed cases and 325,000 deaths. Between the city of
Wuhan, the northern region of Italy, Spain, Germany, and
New York City, this virus will at best be characterized by
pockets of high morbidity and mortality. To date, the best
intervention has been early testing to break the chain of trans-
mission. However, during the first few weeks of this March,
early testing in the United States lagged.(Center for Disease
Control 2020)
As just one of many examples of the faltering roll-out of
diagnostic testing, the United States opted out of receiving a
World Health Organization test kit, which had been shipped to
over 60 other countries by early February. The United States
in particular was slow to provide an alternative to the WHO’s
kits, and the first batch produced by the Centers for Disease
Control (CDC) in February was flawed. By mid-March, the
Department of Health’s test kits were still limited to select
“high-risk” international travelers, or only to patients who
were already critically ill. While there is not a published
national inventory of available test kits—government officials
having kept such numbers confidential—in the second week
of March, in our own state of Indiana, we only had 40 kits
available to test a population of 6.5 million. Well into March,
published values from the United States CDC reported only
several thousand specimens tested in total.(Center for Disease
Control 2020)
As an example of the discordance between testing and
number of cases, retrospective serologic studies of New
York City released on May 2nd representing spread through
the month of March found that up to 12.3% of a state with 8.4
million residents had recovered from the virus.(Cuomo 2020)
Testing using RT-PCR from a comparable time found only ~
67,000 total cases (COVID-19 Tracking Project).
Tech entrepreneurs have already volunteered to fill this gap
in testing need by streamlining how individuals can receive
RT-PCR testing for COVID-19 in many ways. For one innoc-
uous example, the pharmacy conglomerate CVS is offering
limited drive-through testing without a prescription to individ-
uals who self-screen as positive per CDC criteria. Other, more
creative solutions include those by Amazon and the Gates
Foundation, which propose a system where all individuals
could receive screening through an online portal, order a test
kit through the mail, complete testing at home, and then re-
ceive results with instructions on whether and how to self-
quarantine.(Farr 2020) This may sound surprising, but the
current Amazon marketplace already advertises and sells a
variety of the following: paternity, ancestry, allergy antibody,
gut microbiome, colon cancer, and cholesterol home test kits,
all without the restriction of an ordering healthcare provider.
Guidance is instead offered by a “Which DNA test kit should
you get” Amazon-sanctioned editorial, which discusses cus-
tomer service and turn-around time.
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This methodology—which shortcuts the usual healthcare
model of an appointment with a primary care clinician, history
and physical examination, prescription for testing, and follow-
up counseling by phone or in clinic—is considered a primary
feature and not a flaw of a streamlined approach to COVID-19
testing. Evaluating this sort of testing modality is particularly
challenging, because evidence for or against this kind of ex-
panded access will only become available slowly.
Comparative analysis can help us understand what benefits
and risks might exist for direct-to-consumer (DTC) COVID-
19 testing and can be used to generate hypotheses that would
need follow-up research for those individuals who seek out
such testing. As we move forward with home testing, it is
worth remembering that there are lessons to learn from other
at-home testing methodologies. Thus, we suggest a compari-
son of such COVID-19 testing with direct-to-consumer
genetics.
DTC genetic testing is ordered outside of a clinic and with-
out the involvement of a physician. By and large, it has been a
way for the average individual to get genetic testing for a
variety of reasons, including to receive non-clinical knowl-
edge about ancestry as well as alarming and medically action-
able knowledge about pathogenic variants that impute a high
risk of cancer. While such DTC testing has undoubtedly in-
creased access, it has grown to become a parallel bioinformat-
ics market in addition to—but markedly separate from—
clinical services.
Unfortunately, DTC genetics has yet to live up to its prom-
ise. Even after being in use for over two decades, there are still
significant clinical and ethical issues with false positives, false
negatives, outlandish interpretations, privacy, and lack of pre-
and post-test counseling.(Frueh et al. 2011; Kutz 2010;
Stewart et al. 2018; Tandy-Connor et al. 2018) What is per-
haps most concerning is that these criticisms have been ongo-
ing, and issues of privilege and privacy have been identified as
ethical shortcomings since its inception. What is particularly
striking is that DTC genetic testing has not managed to re-
spond fully to these criticisms since they were first levied
many years ago. While some less conscientious DTC genetics
labs may exist, sound advice to patients considering DTC
genetics would still be, “Caveat emptor!”
While features like increased access may underscore
the beneficent impulse underlying such DTC endeavors,
as in the role of the pharmaceutical industry,(Sunder
2006) this does not preclude the concomitant emergence
of ethical quandaries introduced by this novel delivery
model. These actions avoid serious moral scrutiny and
instead are described as “philanthropic,” characterized as
beneficent by the mass media and other public discourse.
But there are other ethical principles to consider, some of
which—like justice—may in fact be at odds with a calcu-
lus of pure beneficence. What mechanisms of access will
guarantee a just distribution of test kits if this process is
overseen by neither the government nor the medical sys-
tem? We must ask ourselves the following: What are the
democratic trade-offs in private versus public authority in
these domains? What checks and balances will control the
private sector’s private interests? How do we incentivize
public entities to maintain their role in the provision of
such care when private entities enter the arena. Likewise,
with important data on COVID-19 sequestered from the
public domain, who will conduct follow-up studies on the
testing that has occurred.
DTC genetics has not proved an equalizing force that de-
mocratizes access to genomic information. Rather, it has
emerged as a novelty available to consumers who currently
have the resources to expend on it. We have already watched
while numerous celebrities have received early COVID-19
testing, raising concerns that financial means and status allow
individuals to utilize a scarce resource unjustly. Moreover,
results from DTC testing are often not reliable enough to be
treated as actionable, and evenwhen they are, it is unclear who
might be liable were these outside results to be used to pre-
scribe a treatment or intervention.(Frueh et al. 2011) If such a
DTC scenario manifests for COVID-19, a well-intentioned,
at-home test for individuals who are worried that they are
infected would offer little more than the generalized advice
published by the WHO, viz. to “Stay home if you feel un-
well.” It is very plausible that DTC COVID-19 testing will
exacerbate the strain on US healthcare rather than provide
necessary relief.
As the world moves forward with COVID-19 testing using
any means possible—including a DTC approach—this com-
parative analysis can generate further studies into what poten-
tial downsides might exist for tests obtained on-demand. It is
true that we need all the help we can get, and every sector will
need to muster resources to fight this pandemic and temper its
associated severe economic hardships. If a DTC method is to
be used, though, it must be done in a manner that provides
relief to the system instead of only to overanxious and eco-
nomically privileged individuals or regions. Test results need
to be integrated into existing healthcare medical records, and
they must be produced in a way that ensures that they are
reliable enough to make sound clinical decisions.
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